You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy

Gilead Sciences has revealed new, four-year data from two Phase III studies evaluating Biktarvy for the treatment of HIV-1 in treatment-naïve adults.